SK biopharmaceuticals Co., Ltd.

Develops and commercializes CNS and oncology therapies for global markets, focusing on the U.S.

326030 | KO

Overview

Corporate Details

ISIN(s):: N/A
LEI:
Country:: South Korea
Address:: 경기도 성남시 분당구 판교역로 221, 성남시
Website:: https://www.skbp.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

SK Biopharmaceuticals is a global, fully integrated pharmaceutical company focused on the discovery, development, and commercialization of innovative therapies. The company's primary therapeutic area is central nervous system (CNS) disorders, with an expanding pipeline in oncology. Its business model encompasses the entire value chain, from research and development to direct commercialization in key global markets, particularly the United States. The company's flagship product is cenobamate (marketed as XCOPRI® in the U.S.), an anti-seizure medication that has demonstrated significant commercial growth. SK Biopharmaceuticals actively incorporates advanced technologies, including artificial intelligence, to accelerate its drug development process and address unmet medical needs.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for SK biopharmaceuticals Co., Ltd. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Date	Filing	Language	Size	Actions
2025-09-16 00:00	Regulatory News Service 투자판단관련주요경영사항	Korean	12.8 KB
2025-08-29 00:00	Regulatory News Service 대규모기업집단현황공시[분기별공시(개별회사용)]	Korean	5.9 KB

Automate Your Workflow. Get a real-time feed of all SK biopharmaceuticals Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for SK biopharmaceuticals Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
GENOLUTION INC. Develops molecular diagnostic and RNAi solutions for genetic testing and life sciences research.	South Korea	225220
Genome&Company Clinical-stage biopharma developing cancer therapies using microbiome, immune inhibitors, and ADCs.	South Korea	314130
Genomictree Inc. Develops molecular diagnostics using DNA methylation biomarkers for early cancer detection.	South Korea	228760
Genomtec S.A. Develops a mobile platform for rapid, precise genetic diagnostics at the point-of-care.	Poland	GMT
GENOTECH CORP. A biotech firm offering gene synthesis, genome analysis, and biopharmaceutical products globally.	South Korea	066830
Gentian Diagnostics ASA Develops & manufactures IVD immunoassays for human & veterinary disease diagnostics.	Norway	GENT
GI Innovation Inc. Develops fusion protein biologics for oncology, allergic, and metabolic diseases.	South Korea	358570
GlaxoSmithKline PLC A biopharmaceutical company developing vaccines and specialty medicines to prevent and treat disease.	United Kingdom	GSK
GL Pharm Tech Corp. Develops improved drugs and generics, and licenses proprietary drug formulation technologies.	South Korea	204840
GNI Group Ltd. Biopharma firm developing novel drugs for cancer and inflammatory diseases using genetics.	Japan	2160